ANAPTYSBIO, INC. (ANAB) Operating Margin
- Operating margin · 12 months: Value 90.80%; Formula and calculation Operating income / revenue. Period ending 2026-06-30..
Operating margin
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Operating margin · 12 months | 90.80% | Operating income / revenue. Period ending 2026-06-30. $215.75M ÷ $237.61M × 100 ≈ 90.80% |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Operating income | 215.75M USD | Operating Income (Loss) |
| Revenue | 237.61M USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Cost of products and services | (m) | |
| Research and development | (m) | Research and Development Expense |
| Selling, general and administration | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Operating income (USD) | Revenue (USD) | Cost of products and services (USD) | Research and development (USD) | Selling, general and administration (USD) | Operating margin |
|---|---|---|---|---|---|---|
| 2026-06-30 | $215.75M | $237.61M | (m) | (m) | (m) | 90.80% |
| 2026-03-31 | $40.80M | $232.39M | (m) | (m) | (m) | 17.56% |
| 2025-12-31 | $47.90M | $234.60M | (m) | (m) | (m) | 20.42% |
| 2025-09-30 | $-28.68M | $169.47M | (m) | (m) | (m) | -16.92% |
| 2025-06-30 | $-86.14M | $123.16M | (m) | (m) | (m) | -69.94% |
| 2025-03-31 | $-100.29M | $111.87M | (m) | (m) | (m) | -89.64% |
| 2024-12-31 | $-114.95M | $91.28M | (m) | (m) | (m) | -125.93% |
| 2024-09-30 | $-147.41M | $57.17M | (m) | (m) | (m) | -257.84% |
| 2024-06-30 | $-162.39M | $30.47M | (m) | (m) | (m) | -532.89% |
| 2024-03-31 | $-162.21M | $22.96M | (m) | (m) | (m) | -706.43% |
| 2023-12-31 | $-164.41M | $17.16M | (m) | (m) | (m) | -958.27% |
| 2023-09-30 | $-148.25M | $14.96M | (m) | $122.13M | (m) | -990.97% |
| 2023-06-30 | $-140.15M | $12.94M | (m) | $113.32M | (m) | -1083.49% |
| 2023-03-31 | $-127.81M | $10.69M | (m) | $101.24M | (m) | -1195.45% |
| 2022-12-31 | $-115.15M | $10.29M | (m) | $88.80M | (m) | -1119.41% |
| 2022-09-30 | $-120.34M | $4.49M | (m) | $92.20M | (m) | -2680.13% |
| 2022-06-30 | $-97.47M | $24.09M | (m) | $92.36M | (m) | -404.65% |
| 2022-03-31 | $-70.20M | $52.90M | (m) | $96.83M | (m) | -132.71% |
| 2021-12-31 | $-56.81M | $63.17M | (m) | $98.50M | (m) | -89.93% |
| 2021-09-30 | $7.69M | $122.16M | (m) | $93.29M | (m) | 6.29% |
| 2021-06-30 | $-9.88M | $101.27M | (m) | $90.61M | (m) | -9.76% |
| 2021-03-31 | $-31.99M | $71.25M | (m) | $83.24M | (m) | -44.90% |
| 2020-12-31 | $-23.88M | $75.00M | (m) | $80.03M | (m) | -31.84% |
| 2020-09-30 | $-79.48M | $18.00M | (m) | $79.88M | (m) | -441.57% |
| 2020-06-30 | $-88.89M | $18.00M | (m) | $90.27M | (m) | -493.84% |
| 2020-03-31 | $-92.91M | $23.00M | (m) | $99.67M | (m) | -403.97% |
| 2019-12-31 | $-107.43M | $8.00M | (m) | $99.34M | (m) | -1342.90% |
| 2019-09-30 | $-104.84M | (m) | (m) | $93.83M | (m) | (m) |
| 2019-06-30 | $-87.98M | (m) | (m) | $81.78M | (m) | (m) |
| 2019-03-31 | $-75.74M | (m) | (m) | $65.02M | (m) | (m) |
| 2018-12-31 | $-66.72M | (m) | (m) | $56.20M | (m) | (m) |
| 2018-09-30 | $-54.21M | (m) | (m) | $47.88M | (m) | (m) |
| 2018-06-30 | $-46.41M | (m) | (m) | $36.70M | (m) | (m) |
| 2018-03-31 | $-34.55M | $10.00M | (m) | $33.32M | (m) | -345.50% |
| 2017-12-31 | $-28.78M | $10.00M | (m) | $29.44M | (m) | -287.81% |
| 2017-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2017-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2017-03-31 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2016-12-31 | $-3.02M | $16.68M | (m) | $15.42M | (m) | -18.13% |
| 2016-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2016-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2016-03-31 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2015-12-31 | $-3.32M | $17.57M | (m) | $17.30M | (m) | -18.91% |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Ultragenyx Pharmaceutical Inc. (RARE) | United States | $1.456B | -5.62 |
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |